公开(公告)号：US20240027473A1

公开(公告)日：2024-01-25

申请号：US18253293

申请日：2021-11-18

Applicant: ASTUTE MEDICAL, INC.

Inventor： PAUL MCPHERSON ,  JAMES PATRICK KAMPF ,  THOMAS KWAN

IPC: G01N33/68 ,  G16H20/40 ,  A61K35/14

CPC classification number: G01N33/6893 ,  G16H20/40 ,  A61K35/14 ,  G01N2800/52 ,  G01N2800/347

Abstract: A method of devising a therapy plan for renal replacement therapy (RRT) includes detecting a level of one or more biomarkers in a body fluid sample obtained from a subject. The level(s) may be correlated to an expected benefit from treatment with continued RRT and/or to an expected ability to successfully discontinue RRT. The method may include the step of assigning the subject to a predetermined subpopulation of individuals exhibiting a known status with regard to meeting criteria for continuing or discontinuing RRT. In some embodiments, the biomarker level is detected by introducing the body fluid into an assay instrument and contacting the body fluid to a binding reagent, for example, an antibody.

公开(公告)号：US11754566B2

公开(公告)日：2023-09-12

申请号：US17085566

申请日：2020-10-30

Applicant: ASTUTE MEDICAL, INC.

Inventor： Joseph Anderberg ,  Jeff Gray ,  Paul McPherson ,  Kevin Nakamura

IPC: G01N33/573 ,  G01N33/68 ,  G01N33/50

CPC classification number: G01N33/573 ,  G01N33/5088 ,  G01N33/5091 ,  G01N33/6893 ,  G01N2800/347 ,  G01N2800/50 ,  G01N2800/56 ,  G01N2800/60

Abstract: Disclosed are methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury The methods use assays that detect one or more markers selected from the group consisting of Cytoplasmic aspartate aminotransferase, soluble Tumor necrosis factor receptor superfamily member 5, soluble CD40 Ligand, soluble C-X-C Motif chemokine 16, SIOO-AI2, Eotaxin, soluble E-selectin, Fibronectin, Granulocyte colony-stimulating factor, Granulocyte-macrophage colony-stimulating factor, Heparin-binding growth factor 2, soluble Hepatocyte growth factor receptor, Interleukin-I receptor antagonist, Interleukin-I beta, lnterleukun-10, lnterieukun-15, lnterieukun-3, Myeloperoxidase, Nidogen-I, soluble Oxidized low-density lipoprotein receptor I, Pappalysin-I, soluble P-selectin glycoprotein ligand I, Antileukoproteinase, soluble Kit ligand, Tissue inhibitor of metalloproteinasel, Tissue inhibitor of metalloproteinase 2, soluble Tumor necrosis factor, soluble Vascular cell adhesion molecule I, and Vascular endothelial growth factor A.

公开(公告)号：US11506672B2

公开(公告)日：2022-11-22

申请号：US15735474

申请日：2016-06-10

Applicant: ASTUTE MEDICAL, INC.

Inventor： Joseph Anderberg ,  Paul McPherson ,  Jeff Gray ,  Kevin Nakamura ,  James Patrick Kampf ,  Thomas Kwan

IPC: G01N33/68

Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more of Follistatin-related protein 3, Basigin, Cathepsin B, and Tenascin as diagnostic and prognostic bio-marker assays in renal injuries.

公开(公告)号：US20220356238A1

公开(公告)日：2022-11-10

申请号：US17621414

申请日：2020-07-01

Applicant: ASTUTE MEDICAL, INC.

Inventor： RAVI A. VIJAYENDRAN ,  HUA WANG

IPC: C07K16/24 ,  G01N33/68

Abstract: The invention provides novel CCL14 antibodies useful in evaluation of renal injuries. In a broad aspect, the present invention provides antibodies which bind CCL14. The provided antibodies can find use in assays to detect CCL14, such as immunoassays with improved clinical performance. In one aspect, the CCL14 antibodies are used in therapeutic methods in which CCL14 binding is desired.

公开(公告)号：US20220236285A1

公开(公告)日：2022-07-28

申请号：US17613766

申请日：2020-05-22

Applicant: ASTUTE MEDICAL, INC.

Inventor： JAMES PATRICK KAMPF ,  THOMAS KWAN ,  PAUL MCPHERSON

IPC: G01N33/68

Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, disclosed herein are methods, compositions, and kits for detecting C-C motif chemokine 14 in combination with creatinine, urine output, and/or cystatin C for predicting the likelihood of persistent acute kidney injury as well as methods for appropriately treating a subject based on his or her assigned likelihood.

公开(公告)号：US11371096B2

公开(公告)日：2022-06-28

申请号：US15521213

申请日：2015-10-22

Applicant: The George Washington University A Congressionally Chartered Not-For-Profit Corporation ,  Astute Medical, Inc.

Inventor： Lakhmir S. Chawla ,  Timothy A. McCaffrey

IPC: C12Q1/6883 ,  G01N33/68 ,  G01N33/566 ,  G01N33/84

Abstract: The invention relates to methods and kits for diagnosing and/or treating appendicitis in a subject, comprising performing one or more assays configured to detect one or more biomarkers on a body fluid sample obtained from the subject to provide one or more assay result(s) and correlating the assay result(s) to the occurrence or nonoccurrence of appendicitis in the subject or likelihood of the future outcome to the subject.

公开(公告)号：US20220187319A1

公开(公告)日：2022-06-16

申请号：US17681493

申请日：2022-02-25

Applicant: ASTUTE MEDICAL, INC.

Inventor： JOSEPH ANDERBERG ,  JEFF GRAY ,  PAUL MCPHERSON ,  KEVIN NAKAMURA ,  JAMES PATRICK KAMPF

IPC: G01N33/68

Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a plurality of assays, one or more of which is configured to detect a kidney injury marker selected from the group consisting of Hyaluronic acid, Immunoglobulin A, Immunoglobulin G1, Immunoglobulin G2, Insulin-like growth factor-binding protein 7, Alpha-1 antitrypsin, Serum amyloid P component, Metalloproteinase inhibitor 2, Hepatocyte growth factor, Intercellular adhesion molecule 1, Beta-2-glycoprotein 1, Interleukin-1 beta, Neutrophil Elastase, Tumor necrosis factor receptor superfamily member HB, Interleukin-11, Cathepsin D, C-C motif chemokine 24, C-X-C motif chemokine 6, C-C motif chemokine 13, C-X-C motif chemokines-1, -2, and -3, Matrilysin, Interleukin-2 receptor alpha chain, Insulin-like growth factor-binding protein 3, and Macrophage colony-stimulating factor 1 as diagnostic and prognostic biomarkers in renal injuries.

公开(公告)号：US20220155324A1

公开(公告)日：2022-05-19

申请号：US17494773

申请日：2021-10-05

Applicant: ASTUTE MEDICAL, INC.

Inventor： JOSEPH ANDERBERG ,  PAUL MCPHERSON ,  JEFF GRAY ,  KEVIN NAKAMURA ,  JAMES PATRICK KAMPF ,  THOMAS KWAN

IPC: G01N33/68

Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more of Insulin-like growth factor-binding protein 2, Insulin-like growth factor-binding protein 3, Insulin-like growth factor-binding protein 4, and Insulin like growth factor-binding protein 6 as diagnostic and prognostic biomarker assays in renal injuries.

公开(公告)号：US11262363B2

公开(公告)日：2022-03-01

申请号：US15676828

申请日：2017-08-14

Applicant: ASTUTE MEDICAL, INC.

Inventor： Joseph Anderberg ,  Jeff Gray ,  Paul McPherson ,  Kevin Nakamura ,  James Patrick Kampf

IPC: G01N33/68

Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a plurality of assays, one or more of which is configured to detect a kidney injury marker selected from the group consisting of Hyaluronic acid, Immunoglobulin A, Immunoglobulin G1, Immunoglobulin G2, Insulin-like growth factor-binding protein 7, Alpha-1 antitrypsin, Serum amyloid P component, Metalloproteinase inhibitor 2, Hepatocyte growth factor, Intercellular adhesion molecule 1, Beta-2-glycoprotein 1, Interleukin-1 beta, Neutrophil Elastase, Tumor necrosis factor receptor superfamily member 11B, Interleukin-11, Cathepsin D, C—C motif chemokine 24, C—X—C motif chemokine 6, C—C motif chemokine 13, C—X—C motif chemokines-1, -2, and -3, Matrilysin, Interleukin-2 receptor alpha chain, Insulin-like growth factor-binding protein 3, and Macrophage colony-stimulating factor 1 as diagnostic and prognostic biomarkers in renal injuries.

公开(公告)号：US11243202B2

公开(公告)日：2022-02-08

申请号：US15565318

申请日：2016-04-08

Applicant: ASTUTE MEDICAL, INC. ,  UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION ,  WESTFÄLISCHE WILHELMS—UNIVERSITÄT MÜNSTER

Inventor： Paul McPherson ,  John A. Kellum, Jr. ,  Alexander Zarbock

IPC: G01N33/566 ,  G01N33/68

Abstract: It is an object of the present invention to provide methods for assessing the efficacy of a remote ischemic preconditioning procedure though the measurement of urinary TIMP-2 and IGFBP7 concentrations.